Events.com apps

Advancing Therapy for Inflammatory Bowel Disease Through Novel Mechanisms and Emerging Agents: A Rapid-Fire Roundtable Discussion

Advancing Therapy for Inflammatory Bowel Disease Through Novel Mechanisms and Emerging Agents: A Rapid-Fire Roundtable Discussion
Image from eventbrite.com
Event ended



This program is intended for Crohn’s and Colitis Congress® attendees only.



Activity Chair

David T. Rubin, MD, AGAF
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL

Faculty

Britt Christensen, BSc, MBBS (Hons), MPH
Head of Inflammatory Bowel Disease
Gastroenterology Department
The Royal Melbourne Hospital
Melbourne, Australia

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC

Alan C. Moss MD, AGAF
Director, Crohn's & Colitis Program
Boston Medical Center
Boston University
Boston, MA


Overview

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic, frequently progressive condition that affects approximately 3 million people in the United States. Inflammatory bowel disease is associated with significant morbidity, diminished quality of life, and, in some cases, mortality. To meet the persistent challenges associated with managing patients with moderate to severe IBD, health care professionals must be knowledgeable regarding the wide variety of existing and emerging agents to treat these diseases. Ongoing education is required to remain current regarding the evidence-based and expert-recommended strategies for managing IBD. In this CME symposium, expert faculty will describe the pathogenesis of IBD and the mechanisms of action of existing and novel therapies, as well as assess the clinical evidence to support the safety and efficacy of emerging agents for treating patients with IBD. This activity will feature Rapid-Fire Roundtable, an engaging, fast-paced exchange of clinical expert perspectives to promote enhanced learning.


Agenda

5:30 AM
Registration and Breakfast

6:00 AM
Introduction and Pretest
David T. Rubin, MD, AGAF

6:05 AM
IBD Pathophysiology and Gaps in Current Therapy
Millie D. Long, MD, MPH

6:20 AM
Rapid-Fire Roundtable Discussion
David T. Rubin, MD, AGAF

6:30 AM
Closing the Gap: Evidence for Emerging Agents in IBD
Alan Moss, MD, AGAF

6:50 AM
Rapid-Fire Roundtable Discussion
David T. Rubin, MD, AGAF

7:00 AM
Smart Approaches to IBD Management
Britt Christensen, BSc, MBBS (Hons), MPH

7:10 PM
Rapid-Fire Roundtable Discussion
David T. Rubin, MD, AGAF

7:20 AM
Posttest

7:25 AM
Question and Answer

7:30 AM
Conclusion


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the known pathways and mechanisms that contribute to the pathogenesis of Crohn’s disease and ulcerative colitis.

  • Compare the mechanisms of action of currently available agents versus novel emerging agents for the management of moderate to severe IBD.

  • Assess the clinical evidence regarding the safety and efficacy of emerging agents for the treatment of IBD.


Target Audience

The intended audience for this activity is gastroenterologists, internists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with IBD.


This continuing medical education activity is provided by the AGA.

In partnership with Vindico Medical Education.

This activity is supported by educational grants from Celgene Corporation and Genentech, Inc.

This program is not affiliated with the Crohn’s and Colitis Congress®.

The American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Gastroenterological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity was planned in accordance with AAPA CME Standards for Live Programs and for Commercial Support of Live Programs.

This education activity is pending approval by the American Association of Nurse Practitioners of up to 1.25 contact hours of accredited education.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Views - 26/01/2020 Last update
culture
e 4th st. 500
hilton austin, austin, 78701, tx, us
Create an event
Create events for free. They will be immediately recommended to interested users.
Nearby hotels and apartments
hilton austin, austin, 78701, tx, us
Discover more events in Austin
Discover now
Discover more events in Austin
Discover now
e 4th st. 500
hilton austin, austin, 78701, tx, us
Create an event
Create events for free. They will be immediately recommended to interested users.
  1. Austin
  2. Advancing Therapy for Inflammatory Bowel Disease Through Novel Mechanisms and Emerging Agents: A Rapid-Fire Roundtable Discussion
 
 
 
 
Your changes have been saved.